Patients Are A Relevant Consumer in the Trademark Confusion Analysis For Biosimilars
Co-authored with Emily Johnston On November 28, 2025, the Federal Court of Appeal (Per Woods JA and Laskin JA) (“FCA”) held that the Federal Court (per Pallotta J) (“FC”) did not err in (1) enjoining Samsung Bioepis (“Samsung”) and Biogen, et al (collectively “Biogen”), as well as their licensees, from using the trademark BYOOVIZ in […]
Patients Are A Relevant Consumer in the Trademark Confusion Analysis For Biosimilars Read More »